For decades, pharma’s commercial logic was built around treating disease once it had already developed. That model is now under pressure.

Across obesity, vaccines, diagnostics, Alzheimer’s disease, women’s health and longevity science, investment is shifting towards earlier intervention – focused on identifying risk sooner, delaying progression and, where possible, preventing disease altogether.

This transition is being driven by both economics and science. Ageing populations and rising healthcare costs are straining healthcare systems, while advances in diagnostics, genomics and biomarker science are making prevention increasingly actionable.

Vaccines remain the clearest example of prevention creating commercial value at scale. Visiongain forecasts the Vaccine Sales Market to grow from US$76.40bn in 2026 to US$141.40bn by 2036, at a CAGR of 6.3% over the forecast period. Alongside investment in diagnostics, obesity management, Alzheimer’s detection, women’s health and longevity science, this shows how pharma value is moving earlier in the disease pathway.

Visiongain top takeaways

• Prevention is becoming commercial: The strongest opportunities sit where earlier intervention can cut downstream costs and support reimbursement.
• Vaccines prove the model: Immunisation has the clearest prevention economics, reducing hospitalisation while supporting health-system resilience.
• Diagnostics are core infrastructure: Early detection only creates value when patients move quickly into the right care pathway.
• Obesity is testing payers: GLP-1 data supports cardiometabolic prevention, but cost and broad eligibility remain major access barriers.
• Women’s health is underpriced: Endometriosis, PCOS and menopause-related risk carry costs still poorly captured in market models.
• Longevity needs harder evidence: The market needs validated biomarkers and clinical endpoints to move beyond wellness positioning.

From late-stage treatment to earlier intervention

Pharma growth has long been built around treating disease after it had already advanced. That model is becoming increasingly difficult to sustain, both economically and clinically.

Payers are pushing back against the cost of late-stage chronic disease, while ageing populations are putting health systems under sustained pressure. At the same time, genomics, biomarker science, mRNA platforms, liquid biopsy and AI-enabled diagnostics are making earlier intervention more practical.

The commercial case is strongest when earlier action changes a reimbursable decision: preventing hospitalisation, delaying progression, reducing complications or identifying patients while treatment can still alter the course of disease. That is why prevention is now showing up across vaccines, diagnostics, obesity management, Alzheimer’s detection and other markets where earlier action could change the cost curve.

The barriers remain significant. Prevention markets depend on screening capacity, patient adherence, long-term outcomes data and payer willingness to fund benefits that may take years to appear.

Visiongain Insight: The winners will not be the companies that simply move earlier in the disease pathway. They will be those that can prove earlier action changes outcomes, reduces avoidable cost and fits into real-world care delivery.

Vaccines: prevention at scale

The prevention model is already becoming visible across multiple healthcare markets, but vaccines remain the clearest proof that earlier intervention can generate both clinical and economic value.

Once viewed in parts of the market as lower-margin, procurement-led public health business, vaccines now have a stronger commercial case. They reduce hospitalisation, protect productivity and can help limit antimicrobial resistance.

COVID-19 accelerated investment in mRNA platforms, manufacturing flexibility, adult immunisation and vaccine supply security. The market is now broadening across RSV, influenza, HPV, oncology vaccines and new mRNA programmes, with opportunities across different age groups and clinical settings.

The revenue model is also widening through booster programmes, seasonal demand, public procurement and adult immunisation. HPV programmes link infectious disease prevention with cancer prevention and women’s health, while therapeutic cancer vaccines point to a broader role beyond conventional prevention.

There are still constraints. Public procurement is price-sensitive, demand can be volatile, and manufacturing capacity, cold-chain logistics, vaccine confidence and regulatory scrutiny all shape market access.

Visiongain Insight: Vaccine growth will increasingly depend on whether companies can treat immunisation as a platform strategy, not a product category: flexible technology, reliable supply, adult uptake and evidence that health systems can defend.

Early diagnostics: the infrastructure problem

If vaccines show prevention working at scale, diagnostics show where the bottlenecks sit.

Liquid biopsies, AI-enabled imaging, genomic assays and biomarker tests are improving earlier detection, especially in oncology, cardiology and neurodegeneration. Companion diagnostics are also becoming more important where therapy uptake depends on finding the right patients quickly.

The value of earlier detection depends on whether it changes what happens next: an actionable treatment decision, a monitoring pathway or a measurable reduction in downstream cost.

The commercial case is less automatic. Diagnostics markets are fragmented, reimbursement can be slow, and adoption depends on clinician confidence, workflow integration and testing access at the point of decision.

Diagnostics will shape prevention markets only when they move beyond detection and into routine, reimbursable care pathways.

Obesity management: the payer test case

Visiongain forecasts the global Anti-obesity Drugs Market to grow from US$22.52bn in 2026 to US$195.99bn by 2036, at a CAGR of 24.2%. That scale explains why obesity has moved from a lifestyle category to one of pharma’s most important cardiometabolic markets.

GLP-1 receptor agonists, led by semaglutide and tirzepatide, are no longer being judged only on weight loss. Outcomes data is strengthening the case for broader benefits across cardiovascular disease, renal disease, sleep apnoea, hepatic disease and type 2 diabetes risk.

That changes the reimbursement argument, but does not settle it. High unit costs and broad eligibility create a difficult budget problem for payers. Visiongain research identifies obesity management as one of the higher-return prevention opportunities, provided companies can demonstrate durable outcomes, appropriate patient selection and manageable long-term costs.

The opportunity is not demand. It is conversion: how much of that demand becomes durable revenue once pricing pressure, supply constraints, adherence and access restrictions are factored in.

Obesity is becoming a test of payer segmentation. The companies best placed to win will be those that can prove which patients benefit most, for how long, and at what long-term cost.

Alzheimer’s detection: earlier intervention, harder reimbursement

Visiongain forecasts the global Alzheimer’s Therapeutics Market to grow from US$6.75bn in 2026 to US$35.76bn by 2036, at a CAGR of 18.2%. The growth case is clear, but the market remains commercially difficult.

Dementia places a major burden on health systems, carers and wider society. Earlier identification could strengthen the clinical and economic case for disease-modifying therapies, particularly before irreversible decline.

Blood-based biomarkers could make early triage less invasive and more scalable. But they do not remove the harder access questions. Alzheimer’s therapies still require clear patient selection, specialist diagnosis, safety monitoring and payer confidence in long-term benefit.

Regulatory momentum may improve, but uptake will depend on whether health systems can diagnose, refer and monitor patients early enough.

Alzheimer’s shows how difficult prevention-led markets can be when evidence, diagnosis and reimbursement all need to align.

Women’s health: the underpriced prevention market

Visiongain forecasts the global Women’s Clinical Trials & CROs Market to grow from US$9.9bn in 2026 to US$22.3bn by 2036, at a CAGR of 8.5%. The growth reflects a wider correction in women’s health, where historically underfunded conditions are attracting greater clinical, regulatory and investment attention.

Women’s health presents a different challenge: significant disease burden has often been under-recognised, underfunded and poorly reflected in commercial models.

Endometriosis, PCOS, maternal complications and menopause-related metabolic decline carry high indirect costs, from delayed diagnosis and repeated consultations to lost productivity and avoidable hospitalisations.

Those costs have been poorly captured in market models, but pipeline activity, investment and policy attention are increasing across historically underfunded areas of women’s health.

The opportunity is not limited to treatment. Earlier hormonal intervention, reproductive metabolic screening, maternal risk stratification and better diagnostic pathways could support earlier, lower-cost care.

Longevity: promise, but evidence still matters

Longevity medicine is trying to shift the market from lifespan extension to healthspan extension.

Visiongain forecasts the global Longevity Market to grow from US$746.00bn in 2026 to US$1,700.64bn by 2036, at a CAGR of 8.6%. The size of the market is clear; the harder question is how much of it becomes evidence-led, reimbursable healthcare.

Senolytics, geroprotectors, biomarker-led diagnostics, AI-enabled discovery and digital health platforms are all part of the field. The economic argument is that delaying age-related morbidity could reduce the time patients spend in high-cost care.

Longevity spans a spectrum: at one end, evidence-led research into senolytics and biomarker-led diagnostics; at the other, wellness marketing with thin scientific backing. The commercially serious opportunity lies at the first end but companies need to prove they belong there.

The commercial landscape: prevention in action

Prevention is becoming a clearer strategic priority for pharma. Capital flows, acquisitions and platform strategies all point in the same direction: companies are looking for growth earlier in the patient journey, before disease becomes more advanced, costly or difficult to treat.

Obesity and cardiometabolic prevention

Novo Nordisk and Eli Lilly remain the leading examples. Their GLP-1 franchises have moved obesity into the centre of pharma growth strategy, supported by outcomes data and demand from patients, clinicians and payers.

Pipeline activity is widening the category beyond first-wave injectables. Novo Nordisk is advancing CagriSema and oral GLP-1 approaches, while Lilly’s tirzepatide franchise has strengthened the case for obesity treatment as cardiometabolic risk reduction.

Roche’s Zealand Pharma agreement, worth up to US$5.3bn, and Pfizer’s Metsera acquisition, worth up to US$10bn, show how quickly obesity has moved from a weight-loss category to a strategic prevention market. Lilly’s acquisition of Verve Therapeutics points to the same wider logic, with cardiovascular risk reduction becoming a target for advanced therapeutic platforms.

The harder question is whether companies can manage pricing pressure, supply, adherence and payer access at scale.

Alzheimer’s early intervention

Lilly’s Kisunla, or donanemab, has strengthened the early Alzheimer’s treatment market, with regulatory progress and longer-term data supporting disease modification before irreversible decline.

The opportunity is large, but adoption will depend on diagnostic access, imaging capacity, safety monitoring, patient selection and payer acceptance.

Digital prevention integration

Novo Nordisk and Eli Lilly are building support services around obesity treatment. Roche’s mySugr platform in diabetes and smart inhaler compatibility around AstraZeneca respiratory products, including Airsupra and Breztri, point in the same direction: the model is shifting from a standalone product to a managed pathway around treatment, monitoring and adherence.

Visiongain Insight: Prevention is becoming an execution test. The companies best placed to win will be those that can make earlier intervention work across evidence, access, infrastructure and patient behaviour.

Market outlook

Prevention-led pharma is set to become a more important growth theme through 2036.

Ageing populations, constrained healthcare budgets and maturing technologies are pushing the market towards earlier intervention. GLP-1 agonists, mRNA vaccines, gene therapy, liquid biopsy and AI-assisted diagnostics are expanding the range of commercially viable prevention models.

But prevention does not automatically lower costs. Earlier diagnosis, broader treatment eligibility and long-term monitoring can add near-term pressure to already stretched budgets.

Markets with strong outcomes evidence, clear patient identification and scalable infrastructure will move faster. Weak evidence, unclear reimbursement or inflated claims will slow adoption.

Visiongain research identifies obesity management, vaccines, early oncology detection, Alzheimer’s intervention, women’s health and longevity as among the most commercially relevant prevention-oriented segments to watch.

Visiongain Insight: Prevention is no longer simply a public-health objective. It is becoming a commercial strategy. From obesity and vaccines to diagnostics, Alzheimer’s disease and women’s health, healthcare investment is moving upstream. The companies that succeed will not necessarily be those that move first. They will be those that can prove earlier intervention improves outcomes, reduces avoidable costs and fits into real-world healthcare delivery. The opportunity is substantial, but it will belong to companies that can turn prevention from scientific promise into commercially sustainable reality.

From Visiongain

Visiongain’s healthcare, pharma and biotech reports provide detailed market forecasts, competitive analysis and sector insight for organisations making decisions across R&D, manufacturing, supply chain, commercial strategy, business development, M&A and investment.

The following reports examine the markets most closely linked to the economics of prevention:

• Vaccine Sales Market Report 2026-2036
• Women’s Clinical Trials & CROs Market Report 2026-2036
• Longevity Market Report 2026-2036
• Anti-obesity Drugs Market Report 2026-2036
• Alzheimer’s Therapeutics Market Report 2026-2036
• Precision Medicine Market Report 2025-2035

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com